## Leslie K Ballas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/243952/publications.pdf

Version: 2024-02-01

38 papers	512 citations	11 h-index	677142 22 g-index
pupozo			S
39 all docs	39 docs citations	39 times ranked	915 citing authors

#	Article	IF	CITATIONS
1	Racial/ethnic disparities in patient experiences with care and Gleason score at diagnosis of prostate cancer: a SEER-CAHPS study. Cancer Causes and Control, 2022, 33, 601-612.	1.8	4
2	Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. Urology, 2021, 148, 198-202.	1.0	2
3	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia and Lymphoma, 2021, 62, 1057-1065.	1.3	4
4	Disparities in male versus female oncologic outcomes following bladder preservation: A populationâ€based cohort study. Cancer Medicine, 2021, 10, 3004-3012.	2.8	6
5	Primary CNS Extranodal Marginal Zone B-Cell Lymphoma: A Case Series of 2 Patients Treated with External Beam Radiation Therapy. Case Reports in Oncology, 2021, 14, 725-732.	0.7	3
6	Concomitant Systemic Therapy: Current and Future Perspectives. Clinical Oncology, 2021, 33, e257-e263.	1.4	3
7	Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial. Cancers, 2021, 13, 2802.	3.7	11
8	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. Anticancer Research, 2021, 41, 3851-3857.	1.1	1
9	National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004–2013. European Urology Oncology, 2020, 3, 343-350.	5.4	6
10	CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?. Practical Radiation Oncology, 2020, 10, e155-e158.	2.1	8
11	Acute Respiratory Events and Dosimetry of Total Body Irradiation Patients Using InÂVivo Lung Dose Monitoring and Custom Lung Block Adaptation. Practical Radiation Oncology, 2020, 10, e397-e405.	2.1	1
12	Testicular Carcinoid Tumor in a Patient With Contralateral Classic Seminoma. Urology, 2020, 141, e32-e34.	1.0	2
13	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. International Journal of Radiation Oncology Biology Physics, 2020, 108, 379-389.	0.8	47
14	Challenges in Reporting the Effect of Radiotherapy on Erectile Function. Journal of Sexual Medicine, 2020, 17, 1053-1059.	0.6	5
15	Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multiâ€institutional analysis. Cancer Medicine, 2020, 9, 3383-3389.	2.8	8
16	Volumetric modulated craniospinal irradiation workflow optimization through quantitative analytics: a single-institution case study comparing pediatric and adult settings. Journal of Radiation Oncology, 2020, 9, 113-121.	0.7	0
17	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e473-e477.	1.9	1
18	Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy. Radiotherapy and Oncology, 2020, 148, 44-50.	0.6	14

#	Article	IF	Citations
19	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 50-60.	0.8	21
20	18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ ng/mL After Definitive Primary Treatment. Clinical Nuclear Medicine, 2019, 44, e128-e132.	1.3	37
21	Trimodality therapy for bladder cancer. Current Opinion in Urology, 2019, 29, 210-215.	1.8	30
22	The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2NORO Prostate Cancer? A Multi-Institutional Study. Advances in Radiation Oncology, 2019, 4, 96-102.	1.2	23
23	Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?. Clinical Genitourinary Cancer, 2018, 16, e719-e727.	1.9	4
24	PSMA PET: Transformational Change in Prostate Cancer Management?. Journal of Nuclear Medicine, 2018, 59, 228-229.	5.0	11
25	Novel Treatment Setup for Urethral Cancer: Use of the Prone Technique for Radiotherapy of the Penis. Case Reports in Oncology, 2018, 11, 268-275.	0.7	2
26	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treatment Reviews, 2018, 70, 88-97.	7.7	26
27	Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study. Cancer Causes and Control, 2018, 29, 815-821.	1.8	17
28	Phase I study of stereotactic body radiotherapy following radical prostatectomy Journal of Clinical Oncology, 2018, 36, TPS158-TPS158.	1.6	1
29	Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2017, 15, 711-716.	1.9	16
30	Current Management Strategy for Penile Cancer and Future Directions. Current Oncology Reports, 2017, 19, 54.	4.0	10
31	Active surveillance: Do low-income patients adhere to the protocol?. Journal of Clinical Oncology, 2017, 35, 53-53.	1.6	1
32	Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity forfirst bone metastases in patients with biochemical recurrence after radical prostatectomy. World Journal of Nuclear Medicine, 2017, 16, 229-236.	0.5	4
33	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clinical Advances in Hematology and Oncology, 2017, 15, 466-477.	0.3	3
34	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
35	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. JAMA Oncology, 2016, 2, 1065.	7.1	36
36	Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. Journal of Urology, 2015, 194, 378-385.	0.4	137

#	Article	IF	CITATIONS
37	Radiosensitivity of orthotopic ileal neobladders Journal of Clinical Oncology, 2015, 33, 350-350.	1.6	O
38	Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncology, The, 2014, 15, 1419-1421.	10.7	1